Jul. 30 at 4:14 PM
$MNKD Another analyst is connecting the dots.
Wells Fargo initiated/updated coverage on
$MNKD with an Overweight rating and a
$14 PT, highlighting that MNKD-201 Phase 1b PK data supports the selected dose while the safety profile remains clean.
Think about what’s happened in just the last week:
1. FUROSCIX ReadyFlow FDA approval
2. Positive MNKD-201 Phase 1b data
3.HC Wainwright reiterates Buy after the updates.
4. Wells Fargo now sees enough in the 201 program to assign a
$14 PT.
The story is evolving beyond Afrezza. Institutions now have multiple value drivers to underwrite: FUROSCIX growth, expanding Tyvaso DPI royalties, potential Ralinepag DPI royalties, and an increasingly credible antifibrotic pipeline led by MNKD-201.
The next major catalyst is execution. If Q2 confirms accelerating commercial momentum and management raises confidence in the outlook, the gap between today’s valuation and analyst price targets may become harder for the market to ignore. Due Diligence.🤞
